Entrada Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M | — | — |
| Operating income | -$157.9M | $47.0M | -$3.2M | -$97.2M | -$51.1M |
| Operating expenses | $183.3M | $163.8M | $132.2M | $97.2M | $51.1M |
| Cash from operations | -$128.5M | -$41.6M | $139.8M | -$93.8M | -$50.9M |
| Capital expenditure | $1.0M | $3.2M | $5.6M | $2.9M | $4.6M |
| Free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M | -$55.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.1M |
Shares outstanding 38.8M · Free float 53.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.